Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders.
The clinical condition and the formation of platelet-reactive antibodies influence the post-transfusion platelet increment. We analysed the specificities of platelet-reactive antibodies in 81 multitransfused patients with haemato-oncological diseases refractory to platelet transfusions, or prior to a scheduled stem cell transplantation. In 17 additional patients we prospectively determined the development of platelet-reactive antibodies at the time of chemotherapy in weekly intervals. Sera were tested by the monoclonal antibody-specific immobilization of platelet antigens (MAIPA)-technique for antiplatelet antibodies against HLA class I antigens, the human platelet-specific alloantigens (HPA)-1, -2, -3, -5, and the platelet membrane glycoproteins (GP) Ia/IIa, Ib/IX, IIb/IIIa (panreactive). Platelet reactive antibodies were found in 54% of blood samples. They were frequent in patients with a history of possible previous immunization, particularly if patients were refractory to platelet transfusions. Platelet-reactive HLA antibodies were the most common antibodies. Even patients without a known risk of primary immunization who received exclusively leucocyte-depleted blood products formed antibodies. By the MAIPA technique, even LCT-negative sera were found to contain platelet-reactive antibodies.
Kurz
M
M
Clinic for Blood Group Serology and Transfusion Medicine, University of Vienna, Austria.
Greinix
H
H
Höcker
P
P
Kalhs
P
P
Knöbl
P
P
Mayr
W R
WR
Pober
M
M
Panzer
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000918:Antibody Specificity; D001792:Blood Platelets / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007223:Infant; D008875:Middle Aged; D017713:Platelet Transfusion; D011446:Prospective Studies